Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
2.550
+0.210 (8.97%)
May 19, 2025, 4:00 PM - Market closed
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $1.32M in the quarter ending March 31, 2025, with 331.69% growth. This brings the company's revenue in the last twelve months to $6.22M, up 256.35% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$6.22M
Revenue Growth
+256.35%
P/S Ratio
0.39
Revenue / Employee
$778,010
Employees
8
Market Cap
3.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ENSC News
- 6 days ago - Ensysce Biosciences Reports First Quarter 2025 Financial Results - Accesswire
- 8 days ago - Ensysce Biosciences Bolsters Management Team with Regulatory Expert - Accesswire
- 25 days ago - Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds - Accesswire
- 26 days ago - Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why - Benzinga
- 26 days ago - Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds - Accesswire
- 27 days ago - Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder - Accesswire
- 5 weeks ago - Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study - Accesswire
- 7 weeks ago - Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire